ICON Public (NASDAQ:ICLR) Price Target Lowered to $270.00 at Leerink Partners

ICON Public (NASDAQ:ICLR) had its target price decreased by Leerink Partners from $376.00 to $270.00 in a report issued on Friday morning, Benzinga reports. Leerink Partners currently has an outperform rating on the medical research company’s stock.

Other analysts also recently issued reports about the company. Truist Financial dropped their price objective on ICON Public from $383.00 to $363.00 and set a “buy” rating for the company in a report on Monday, October 14th. Redburn Atlantic assumed coverage on shares of ICON Public in a research note on Monday, October 14th. They issued a “neutral” rating and a $311.00 target price on the stock. Barclays dropped their price objective on shares of ICON Public from $350.00 to $330.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 15th. Evercore ISI dropped their price target on shares of ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Finally, Baird R W cut shares of ICON Public from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, ICON Public currently has an average rating of “Moderate Buy” and a consensus target price of $304.27.

ICON Public Price Performance

Shares of ICLR opened at $230.50 on Friday. ICON Public has a twelve month low of $220.01 and a twelve month high of $347.72. The stock’s 50 day moving average is $295.86 and its two-hundred day moving average is $309.61. The firm has a market capitalization of $19.02 billion, a PE ratio of 26.86, a P/E/G ratio of 1.35 and a beta of 1.22. The company has a current ratio of 1.31, a quick ratio of 1.31 and a debt-to-equity ratio of 0.36.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing the consensus estimate of $3.72 by ($0.37). ICON Public had a return on equity of 12.06% and a net margin of 8.57%. The firm had revenue of $2.03 billion for the quarter, compared to analysts’ expectations of $2.13 billion. During the same period last year, the firm earned $3.10 EPS. ICON Public’s revenue was down 1.2% compared to the same quarter last year. Research analysts anticipate that ICON Public will post 14.53 earnings per share for the current year.

Institutional Trading of ICON Public

A number of large investors have recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC acquired a new stake in shares of ICON Public during the 2nd quarter worth about $54,000. ORG Partners LLC acquired a new stake in shares of ICON Public during the 2nd quarter worth about $59,000. Whittier Trust Co. of Nevada Inc. lifted its stake in shares of ICON Public by 410.8% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 189 shares of the medical research company’s stock worth $63,000 after buying an additional 152 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of ICON Public by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock worth $82,000 after buying an additional 87 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of ICON Public by 17.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock worth $95,000 after buying an additional 42 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.